Literature DB >> 28244856

TRIM11 Upregulation Contributes to Proliferation, Invasion, and EMT of Hepatocellular Carcinoma Cells.

Zewei Zhang, Chao Xu, Xiafang Zhang, Lulu Huang, Cheng Zheng, Haitao Chen, Yan Wang, Haixing Ju, Qinghua Yao.   

Abstract

The tripartite motif-containing protein 11 (TRIM11), a member of the TRIM protein family, has attracted much attention because of its involvement in the development of the central nervous system. It has gained renewed focus because of its newly found function in promoting tumors. However, little is known about its role in hepatocellular carcinoma (HCC). In the present study, we found TRIM11 to be overexpressed in HCC tissues and cell lines. Downregulation of TRIM11 inhibited HCC cell proliferation and invasion in vitro and in vivo as well as suppressed the epithelial-mesenchymal transition (EMT) process. In addition, downregulation of TRIM11 decreased the protein expression levels of p-PI3K and p-Akt in HCC cells and thus inhibited activation of the PI3K/Akt signaling pathway. Based on these results, we suggest the importance of TRIM11 in HCC progression and the potential of TRIM11 as a therapeutic target for HCC.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 28244856     DOI: 10.3727/096504016X14774897404770

Source DB:  PubMed          Journal:  Oncol Res        ISSN: 0965-0407            Impact factor:   5.574


  21 in total

1.  TRIM11 promotes tumor angiogenesis via activation of STAT3/VEGFA signaling in lung adenocarcinoma.

Authors:  Jiaru Huang; Laiqin Tang; Yunfeng Zhao; Wei Ding
Journal:  Am J Cancer Res       Date:  2019-09-01       Impact factor: 6.166

Review 2.  The roles of E3 ligases in Hepatocellular carcinoma.

Authors:  Zongdong Yu; Hong Li; Jie Zhu; Haibiao Wang; Xiaofeng Jin
Journal:  Am J Cancer Res       Date:  2022-03-15       Impact factor: 6.166

3.  Sex-determining Region Y-box transcription factor 13 promotes breast cancer cell proliferation and glycolysis by activating the tripartite motif containing 11-mediated Wnt/β-catenin signaling pathway.

Authors:  Xiaoyan Jin; Xuan Shao; Wenyang Pang; Zhengyi Wang; Jian Huang
Journal:  Bioengineered       Date:  2022-05       Impact factor: 6.832

Review 4.  TRIM family contribute to tumorigenesis, cancer development, and drug resistance.

Authors:  Ning Huang; Xiaolin Sun; Peng Li; Xin Liu; Xuemei Zhang; Qian Chen; Hong Xin
Journal:  Exp Hematol Oncol       Date:  2022-10-19

5.  Tripartite Motif Containing 52 (TRIM52) Promotes Cell Proliferation in Hepatitis B Virus-Associated Hepatocellular Carcinoma.

Authors:  Yi Zhang; Shan-Shan Wu; Xiao-Hua Chen; Zheng-Hao Tang; Yong-Sheng Yu; Guo-Qing Zang
Journal:  Med Sci Monit       Date:  2017-11-01

6.  TRIM11 promotes breast cancer cell proliferation by stabilizing estrogen receptor α.

Authors:  Jianing Tang; Yongwen Luo; Zelin Tian; Xing Liao; Qiuxia Cui; Qian Yang; Gaosong Wu
Journal:  Neoplasia       Date:  2020-06-27       Impact factor: 5.715

7.  TRIM11 facilitates chemoresistance in nasopharyngeal carcinoma by activating the β-catenin/ABCC9 axis via p62-selective autophagic degradation of Daple.

Authors:  Runa Zhang; Si-Wei Li; Lijuan Liu; Jun Yang; Guofu Huang; Yi Sang
Journal:  Oncogenesis       Date:  2020-05-07       Impact factor: 7.485

8.  Downregulation of tripartite motif protein 11 attenuates cardiomyocyte apoptosis after ischemia/reperfusion injury via DUSP1-JNK1/2.

Authors:  Fang He; Zheqian Wu; Yong Wang; Lili Yin; Shijie Lu; Lihua Dai
Journal:  Cell Biol Int       Date:  2021-11-10       Impact factor: 4.473

9.  LncRNA NR2F1-AS1 regulates hepatocellular carcinoma oxaliplatin resistance by targeting ABCC1 via miR-363.

Authors:  Hai Huang; Jie Chen; Cheng-Ming Ding; Xin Jin; Ze-Ming Jia; Jian Peng
Journal:  J Cell Mol Med       Date:  2018-03-30       Impact factor: 5.310

10.  TRIM52 up-regulation in hepatocellular carcinoma cells promotes proliferation, migration and invasion through the ubiquitination of PPM1A.

Authors:  Yi Zhang; Ran Tao; Shan-Shan Wu; Cui-Cui Xu; Jie-Ling Wang; Jie Chen; Yong-Sheng Yu; Zheng-Hao Tang; Xiao-Hua Chen; Guo-Qing Zang
Journal:  J Exp Clin Cancer Res       Date:  2018-06-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.